Francis D'orazi, DO
Pulmonary Disease · Port Jefferson Station, NYNPI 1346401262
Payments from drug & device makers
Across 626 payments — averaging $21.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$3K
- Boehringer Ingelheim$1K
- Electromed, Inc.$899
- Grifols USA, LLC$651
- Mylan Specialty L.p.$503
- plus $3K from 31 others
What the payments were for
- Food & beverage$13,544100%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 167 | $3,352 |
| AstraZeneca | 110 | $3,283 |
| Boehringer Ingelheim | 72 | $1,483 |
| Electromed, Inc. | 74 | $899 |
| Grifols USA, LLC | 29 | $651 |
| Mylan Specialty L.p. | 22 | $503 |
| Baxter Healthcare | 18 | $476 |
| Sanofi | 16 | $381 |
| Insmed, Inc. | 16 | $345 |
| Regeneron Healthcare Solutions, Inc. | 18 | $343 |
| Merck | 14 | $229 |
| Verona Pharma, Inc. | 8 | $180 |
| Harmony Biosciences LLC | 7 | $178 |
| ANI Pharmaceuticals, Inc. | 5 | $137 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $123 |
| Amgen | 5 | $97 |
| Vifor Pharma, Inc. | 4 | $94 |
| Advanced Respiratory, Inc | 3 | $79 |
| Inogen, Inc. | 3 | $69 |
| Jazz Pharmaceuticals Inc. | 3 | $66 |
| Genentech USA, Inc. | 3 | $61 |
| Lilly USA, LLC | 2 | $60 |
| Viatris Specialty LLC | 2 | $53 |
| Teva Pharmaceuticals USA, Inc. | 2 | $51 |
| Kvk-tech, Inc. | 1 | $49 |
| Novartis | 2 | $48 |
| Philips North America LLC | 3 | $45 |
| Sunovion Pharmaceuticals Inc. | 2 | $41 |
| Pfizer | 2 | $40 |
| Tandem Diabetes Care, Inc. | 2 | $39 |
| Nabriva Therapeutics, PLC | 1 | $20 |
| Phadia US Inc. | 1 | $19 |
| Optinose US, Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
| Mannkind Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,570 in reported general payments places this provider in the 80th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 495 | $376,547 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 277 | $185,674 |
| Dupixent PenDupilumab | 41 | $174,469 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 104 | $58,557 |
| Spiriva RespimatTiotropium Bromide | 78 | $41,800 |
| Breo ElliptaFluticasone/Vilanterol | 75 | $38,206 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 71 | $37,938 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 493 | $16,077 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 57 | $8,831 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $8,617 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $6,937 |
| BreynaBudesonide/Formoterol Fumarate | 11 | $2,538 |
| Fluticasone Propionate | 112 | $1,514 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 30 | $1,454 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,352 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $3,352 | $473,310674 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,283 | $194,291302 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $1,483 | $79,738149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Port Jefferson Station
- Keith HarrisPort Jefferson Station$854K
- Yuval HiltzikPort Jefferson Station$282K
- Peter OttavioPort Jefferson Station$269K
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.